Zevra Therapeutics (ZVRA) EPS (Basic) Growth (3y) (2017 - 2026)
Powered by 
Analysis
Zevra Therapeutics (ZVRA) EPS (Basic) Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 86.03% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 18.44% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.21% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.73% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -38.31% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 67.51% |
| 10 | Zevra Therapeutics | 734.60 Mn | 513.03 Mn | 38.18 Mn | 58.06% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 58.06% |
| Mar 31, 2026 | 57.41% |
| Dec 31, 2025 | 41.63% |
| Sep 30, 2025 | 53.37% |
| Jun 30, 2025 | 80.78% |
| Mar 31, 2025 | -28.48% |
| Dec 31, 2024 | -157.22% |
| Sep 30, 2024 | -203.04% |
| Jun 30, 2024 | -37.41% |
| Mar 31, 2024 | 31.66% |
| Dec 31, 2023 | 2.74% |
| Sep 30, 2023 | 4.24% |
| Jun 30, 2023 | -39.21% |
| Mar 31, 2023 | 29.09% |
| Dec 31, 2022 | 45.64% |
| Sep 30, 2022 | -28.42% |
| Jun 30, 2022 | 48.86% |
| Mar 31, 2022 | 80.57% |
| Dec 31, 2021 | 73.02% |
| Sep 30, 2021 | 85.08% |